Close Asset Management
MRNA icon

Close Asset Management’s Moderna MRNA Stock Holding History

Close Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7K Buy
+35
New +$3.77K ﹤0.01% 221
2026
Q1 		– Sell
-75
Closed -$2K – 283
2025
Q4 		$2K Hold
75
– – ﹤0.01% 260
2025
Q3 		$2K Sell
75
-100
-57% -$2.79K ﹤0.01% 254
2025
Q2 		$5K Sell
175
-500
-74% -$13.2K ﹤0.01% 230
2025
Q1 		$19K Hold
675
– – ﹤0.01% 192
2024
Q4 		$28K Hold
675
– – ﹤0.01% 176
2024
Q3 		$45K Hold
675
– – ﹤0.01% 166
2024
Q2 		$80K Buy
675
+75
+13% +$9.49K ﹤0.01% 146
2024
Q1 		$64K Buy
600
+250
+71% +$25.2K ﹤0.01% 151
2023
Q4 		$35K Hold
350
– – ﹤0.01% 162
2023
Q3 		$36K Buy
350
+80
+30% +$8.92K ﹤0.01% 153
2023
Q2 		$33K Buy
270
+250
+1,250% +$33.4K ﹤0.01% 173
2023
Q1 		$3K Buy
+20
New +$3.3K ﹤0.01% 220
2021
Q4 		– Sell
-36
Closed -$14K – 211
2021
Q3 		$14K Buy
+36
New +$13.3K ﹤0.01% 178

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Close Asset Management's MRNA Position: Q3 2026 in Review

Close Asset Management opened a new position in Moderna (MRNA) in Q3 2026: 35 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #221 among its holdings. This is a return to the name: Close Asset Management previously reported a position in MRNA as recently as Q4 2025.

Close Asset Management first reported a position in MRNA in Q3 2021 and has held it in 14 quarters since. The position peaked at $80K in Q2 2024. 805 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Close Asset Management held 35 shares of Moderna worth $7K as of Q3 2026.
  • Moderna was a new Close Asset Management position in Q3 2026.
  • Moderna made up ﹤0.01% of Close Asset Management's portfolio in Q3 2026, its #221 holding.
  • Close Asset Management first reported a position in Moderna in Q3 2021 and has held it in 14 quarters since.
  • Close Asset Management's Moderna position peaked at $80K in Q2 2024.
  • 805 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Close Asset Management's 13F filing for Q3 2026, filed 30 Oct 2026.